Navigation Links
New study suggests Rx estrogen delivery through the skin may show safety benefits as opposed to oral delivery
Date:3/26/2009

NEW YORK, NY (March 25, 2009) Transdermal delivery of estrogen therapy available by prescription "seems not to alter" the risk of venous thromboembolism (VTE), or blood clotting, in postmenopausal patients when compared to oral delivery, a new study suggests. The study was conducted by researchers at NYU Langone Medical Center and was published in the latest issue of Menopause: The Journal of the North American Menopause Society.

Prescription transdermal estrogen therapy is bioidentical to estrogen produced by a woman's ovaries before menopause and delivered through the skin. Transdermal estrogen is available in a variety of formulations which have been quality controlled and approved safe and effective by the United States Food and Drug Administration (FDA).

The team at NYU Langone sought to determine the effects of delivery of estrogen therapy on postmenopausal women. Blood obtained from 84 postmenopausal women was tested for clotting activity before and after administration of oral or transdermal estrogen for a period of eight weeks. Women with borderline clotting issues showed "a significant acceleration" of clotting after oral estrogen therapy, but no significant change after transdermal estrogen therapy.

"Venous thromboembolic complications or blood clots represent an established risk factor of estrogen therapy, and evidence is now mounting that the route of estrogen administration influences this risk," said researcher Lila Nachtigall, M.D., Director of the Women's Wellness Program at NYU. "These new data on the safety of transdermal HT delivery may prove to be useful information for postmenopausal women deciding whether to take estrogen therapy and whether to take it orally or through the skin."

The research team studied platelet activity in the study participants' blood. Platelets serve a central role in forming pathological arterial thrombosis that causes myocardial infarction and stroke. The study's authors further concluded that the ability to identify postmenopausal women with an increased risk of arterial thrombosis or clotting before even starting estrogen therapy is an important goal to help physicians determine which women may be at the least risk to benefit from estrogen therapy.

"The effect of estrogen therapy on cardiovascular risk remains a point of controversy; however, these data suggest that estrogen delivered transdermally may not increase the likelihood of clotting for women who are at borderline risk," said Dr. Nachtigall. "This study supports the emerging data suggesting that oral, not transdermal estrogen may increase the risk of venous thromboembolism in postmenopausal women."


'/>"/>

Contact: Lorinda Klein
lorindaann.klein@nyumc.org
212-404-3533
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related medicine news :

1. Autism Study Finds Significant Benefit with Hyperbaric Treatment
2. Danon Disease Can Be Quickly Fatal, Study Finds
3. NYU study finds new risk factor for melanoma in younger women
4. Study helps identify college drinkers who might continue excessive drinking as adults
5. Study finds program has improved health agencies preparedness for bioterror and disease outbreaks
6. GAO Study Links Duty Circumvention with Evasion of Food Safety Laws
7. Study IDs Variations in Black, White Genomes
8. Researchers studying hearing loss find auditory regions of the brain convert to the sense of touch
9. Pilot Study Using Video Cell Phones for Mobile Direct Observation Treatment (MDOT) to Monitor Medication Compliance of TB Patients
10. Study shows how Salmonella survives in environment
11. Study IDs Gene Variants Tied to Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... With less than 10,000 dermatologists in the United States and ... limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... online, today released its inaugural survey on the State of Acne in America. ...
(Date:3/28/2017)... Petersburg Florida (PRWEB) , ... March 28, 2017 , ... ... Marine Corp to raise money to for the Toys for Tots Literacy Campaign at ... federal budget in excess of $70 billion, the U.S. ranks at number 14 internationally ...
(Date:3/28/2017)... ... March 28, 2017 , ... AutismOne announced the Board Certified ... Integrative Medicine and available for application on Saturday, May 27, 2017, following Thursday, ... Colorado Springs. , Ed Arranga, president of AutismOne, stated: "Many of the modalities ...
(Date:3/28/2017)... NJ (PRWEB) , ... March 28, 2017 , ... ... Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a busy ... their team of professional staff discussed strategies for preventing outbreaks among camp communities ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in ... has a lot to offer to the discussion of dealing with excess skin oil. ... there are many home remedies that can help remove the oily shine while keeping the ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 Medtec Europe ... more than 600 exhibitors from 70 countries the ... solutions that will advance the medical technology industry. ... the Messe Stuttgart, Stuttgart, Germany ... platform showcasing the key trends and insights across ...
(Date:3/27/2017)... March 27, 2017  Sophiris Bio Inc. (NASDAQ: ... a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) ... today reported fourth quarter and full year 2016 ... Key Corporate Highlights: Advanced ... Cancer. During 2016, the Company reported successful results ...
(Date:3/27/2017)... VANCOUVER , March 27, 2017 /PRNewswire/ - INVICTUS ... OTC: IVITF; FRA: 8IS) Invictus MD is pleased to ... common shares for trading on the TSX Venture Exchange.  ... the TSXV follows a year of significant achievements for ... The successful test crops at AB Laboratories Inc. ("AB ...
Breaking Medicine Technology: